“补肾祛瘀”针法治疗勃起功能障碍的临床研究

注册号:

Registration number:

ITMCTR2024000852

最近更新日期:

Date of Last Refreshed on:

2024-12-22

注册时间:

Date of Registration:

2024-12-22

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

“补肾祛瘀”针法治疗勃起功能障碍的临床研究

Public title:

Clinical study on the treatment of erectile dysfunction by "Tonifying kidney and removing blood stasis" acupuncture therapy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

“补肾祛瘀”针法治疗勃起功能障碍的临床研究

Scientific title:

Clinical study on the treatment of erectile dysfunction by "Tonifying kidney and removing blood stasis" acupuncture therapy

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

晏明熙

研究负责人:

崔瑾

Applicant:

Yan Mingxi

Study leader:

Cui Jin

申请注册联系人电话:

Applicant telephone:

+86 152 0835 3177

研究负责人电话:

Study leader's telephone:

+86 139 8502 6278

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

435294123@qq.com

研究负责人电子邮件:

Study leader's E-mail:

516260179@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

中国贵州省贵阳市南明区市东路50号

研究负责人通讯地址:

中国贵州省贵阳市南明区市东路50号

Applicant address:

No.50 Shidong Road Nanming District Guiyang City Guizhou Province China

Study leader's address:

No.50 Shidong Road Nanming District Guiyang City Guizhou Province China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

贵州中医药大学

Applicant's institution:

Guizhou University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

KH2024-002A

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

贵州中医药大学第一附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Guizhou University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024/9/13 0:00:00

伦理委员会联系人:

王宝娟

Contact Name of the ethic committee:

Wang Baojuan

伦理委员会联系地址:

贵州省贵阳市云岩区宝山北路71号

Contact Address of the ethic committee:

No.71 Baoshan North Road Yunyan District Guiyang City Guizhou Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 156 8513 0972

伦理委员会联系人邮箱:

Contact email of the ethic committee:

775087642@qq.com

研究实施负责(组长)单位:

贵州中医药大学第一附属医院

Primary sponsor:

The First Affiliated Hospital of Guizhou University of Chinese Medicine

研究实施负责(组长)单位地址:

贵州省贵阳市云岩区宝山北路71号

Primary sponsor's address:

No.71 Baoshan North Road Yunyan District Guiyang City Guizhou Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

贵州省

市(区县):

贵阳

Country:

China

Province:

Guizhou

City:

Guiyang

单位(医院):

贵州中医药大学第一附属医院

具体地址:

贵州省贵阳市云岩区宝山北路71号

Institution
hospital:

The First Affiliated Hospital of Guizhou University of Chinese Medicine

Address:

The First Affiliated Hospital of Guizhou University of Chinese Medicine

经费或物资来源:

重点研发项目转校内课题

Source(s) of funding:

Key research and development projects transferred to campus subjects

研究疾病:

勃起功能障碍

研究疾病代码:

Target disease:

Erectile dysfunction

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

本研究以ED患者为观察对象,研究针刺对ED患者勃起功能指数、勃起质量、性激素及血管内皮功能的影响,其研究结果将用于为针刺的临床应用提供循证证据,以促进针刺临床治疗ED疗效的提升,拓展针刺相关理论的发展。

Objectives of Study:

The purpose of this study is to observe and compare the clinical efficacy and safety of electroacupuncture and western medicine in ED patients and the research results will be used to provide evidence-based evidence for the clinical application of electroacupuncture so as to promote the improvement of the clinical efficacy of acupuncture in the treatment of ED and expand the development of acupuncture related theories.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合上述病证诊断标准; (2)年龄在20-60岁,IIEF-5 评分在 5-21 分之间且病程≥3个月; (3)性欲正常,有固定性伴侣者; (4)一个月内未接受任何与本病相关的治疗; (5)愿意配合研究,患者签署知情同意书。

Inclusion criteria

(1) meet the diagnostic criteria for the above diseases; (2) Age 20-60 years old IIEF-5 score between 5-21 points and duration of disease ≥3 months; (3) Normal sexual desire a fixed sexual partner; (4) have not received any treatment related to the disease within one month; (5) Willing to cooperate with the study patients sign informed consent.

排除标准:

(1)有明显器质性损害者; (2)合并有严重心脑血管疾病或其他肝、肾、血液、内分泌疾病及精神疾病者; (3)服用硝酸酯类药物者; (4)有低血压或高血压未控制者; (5)因激素、神经性因素导致的阳痿; (6)本对研究药物过敏者; (7)因晕针、凝血功能障碍等原因不能行针刺治疗或不接受电针治疗者。

Exclusion criteria:

(1) There is obvious organic damage; (2) Patients with severe cardiovascular and cerebrovascular diseases or other liver kidney blood endocrine diseases and mental diseases; (3) Taking nitric ester drugs; (4) Patients with hypotension or uncontrolled hypertension; (5) impotence caused by hormones and neurological factors; (6) Those who are allergic to the study drug; (7) Patients who cannot perform acupuncture treatment or do not receive electroacupuncture treatment due to acupuncture dizziness coagulation dysfunction and other reasons.

研究实施时间:

Study execute time:

From 2024-12-27

To      2025-12-27

征募观察对象时间:

Recruiting time:

From 2024-12-30

To      2025-10-01

干预措施:

Interventions:

组别:

西药组

样本量:

31

Group:

Western medicine section

Sample size:

干预措施:

口服他达拉非片

干预措施代码:

Intervention:

Tadalafil tablets

Intervention code:

组别:

电针组

样本量:

31

Group:

Electroacupuncture set

Sample size:

干预措施:

电针

干预措施代码:

Intervention:

electroacupuncture

Intervention code:

样本总量 Total sample size : 62

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

贵州

市(区县):

贵阳

Country:

China

Province:

Guizhou

City:

Guiyang

单位(医院):

贵州中医药大学第一附属医院

单位级别:

三甲

Institution/hospital:

The First Affiliated Hospital of Guizhou University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

中医临床证候评分

指标类型:

次要指标

Outcome:

TCM clinical syndrome integral

Type:

Secondary indicator

测量时间点:

治疗前,治疗两周,治疗结束时,治疗结束后1个月

测量方法:

量表

Measure time point of outcome:

Before treatment, two weeks of treatment, at the end of treatment, and 1 month after treatment

Measure method:

scale

指标中文名:

勃起质量量表

指标类型:

次要指标

Outcome:

Erection Quality Scale

Type:

Secondary indicator

测量时间点:

治疗前,治疗两周,治疗结束时,治疗结束后1个月

测量方法:

量表

Measure time point of outcome:

Before treatment, two weeks of treatment, at the end of treatment, and 1 month after treatment

Measure method:

scale

指标中文名:

国际勃起功能指数问卷

指标类型:

次要指标

Outcome:

Erectile Function Domain of the International Index of Erectile Function

Type:

Secondary indicator

测量时间点:

治疗前,治疗两周,治疗结束时,治疗结束后1个月

测量方法:

量表

Measure time point of outcome:

Before treatment, two weeks of treatment, at the end of treatment, and 1 month after treatment

Measure method:

scale

指标中文名:

抑郁自评量表

指标类型:

次要指标

Outcome:

Self-rating Depression Scale

Type:

Secondary indicator

测量时间点:

治疗前,治疗两周,治疗结束时,治疗结束后1个月

测量方法:

量表

Measure time point of outcome:

Before treatment, two weeks of treatment, at the end of treatment, and 1 month after treatment

Measure method:

scale

指标中文名:

国际勃起功能问卷-5

指标类型:

主要指标

Outcome:

International Erectile Function Questionnaire-5

Type:

Primary indicator

测量时间点:

治疗前,治疗两周,治疗结束时,治疗结束后1个月

测量方法:

量表

Measure time point of outcome:

Before treatment two weeks of treatment at the end of treatment and 1 month after treatment

Measure method:

scale

指标中文名:

焦虑自评量表

指标类型:

次要指标

Outcome:

Self-rating Anxiety Scale

Type:

Secondary indicator

测量时间点:

治疗前,治疗两周,治疗结束时,治疗结束后1个月

测量方法:

量表

Measure time point of outcome:

Before treatment, two weeks of treatment, at the end of treatment, and 1 month after treatment

Measure method:

scale

指标中文名:

血清性激素

指标类型:

次要指标

Outcome:

Serum sex hormone

Type:

Secondary indicator

测量时间点:

治疗前,治疗30天

测量方法:

肘静脉取血

Measure time point of outcome:

Before treatment treatment for 30 days

Measure method:

Take blood from the cubital vein

指标中文名:

安全性评价

指标类型:

副作用指标

Outcome:

Safety evaluation

Type:

Adverse events

测量时间点:

针刺治疗或用药期间

测量方法:

记录试验过程中出现的安全事件

Measure time point of outcome:

During acupuncture treatment or medication

Measure method:

Record safety incidents that occur during the test

指标中文名:

血管内皮功能

指标类型:

次要指标

Outcome:

Vascular endothelial function

Type:

Secondary indicator

测量时间点:

治疗前,治疗30天

测量方法:

肘静脉取血

Measure time point of outcome:

Before treatment treatment for 30 days

Measure method:

Take blood from the cubital vein

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血清

组织:

肘部静脉采血

Sample Name:

Serum

Tissue:

Blood was taken from an elbow vein

人体标本去向

使用后销毁

说明

检测性激素及血管内皮功能

Fate of sample 

Destruction after use

Note:

Sex hormones and vascular endothelial function were measured

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 20
Min age years
最大 60
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男性

Male

随机方法(请说明由何人用什么方法产生随机序列):

与试验操作无关人员采用SPSS 26.0软件获取随机号,得出顺序号、随机种子数、分组结果。

Randomization Procedure (please state who generates the random number sequence and by what method):

SPSS26.0 software was used to obtain random number sequence number random seed number and grouping results.

盲法:

由于本试验操作的特殊性,无法对操作者和患者设盲,故对结局评价者设盲,即由与试验操作无关的人员进行数据统计和结局评估。

Blinding:

Due to the particularity of the operation of this experiment the operator and the patient could not be blinded so the outcome evaluator was blinded that is the data statistics and outcome evaluation were carried out by personnel unrelated to the operation of the experiment.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

通过发表期刊文章公开原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

by publication

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统